Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Genelabs Technologies
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Patient must have a diagnosis of SLE \> 6 months according to the 1989 revised ACR criteria. Patient must meet at least four of the eleven ACR criteria for systemic lupus
Patient must have a modified SLEDAI score \> 3 at both screening and qualifying visits (Appendix A-2)
Patient must be treated for SLE with doses of prednisone \< 30 mg/day (including those on NO glucocorticoid therapy) unchanged for \> 6 weeks prior to study entry (including both screening and qualifying visits). Prednisone dose in patient's receiving alternate day therapy will be the mean daily prednisone dose
Patient treated with azathioprine, methotrexate, or hydrochloroquine must be on a stable dose with no change in dose for at least 6 weeks preceding the study
Patient must be able to read and speak English and willing to sign an informed consent in English
You may not be if
Patient with a history of prostate cancer
Patient with elevated Prostate Specific Antigen (PSA)
Patient diagnosed with liver disease, defined as AST or ALT \> 3x the upper limit of normal
Patient ingesting body building/anabolic steroids within the last 6 months preceding the study
Patient with end stage renal disease or receiving hemodialysis treatment
Patient with serum creatinine \> 2 mg/dl or creatinine clearance \< 60 ml/min
Patient receiving treatment with ACTH within the 3 months preceding study entry
Patient receiving androgens, immunoglobulins, cyclophosphamide, cyclosporin A, or other immunosuppressive agents, except azathioprine, methotrexate, and hydrochloroquine within the last 3 months
Patient with known hypersensitivity to DHEA or the inactive ingredients used in the GL70l formulation (cornstarch, lactose, and magnesium stearate)
Patient who participated in any prior DHEA study or administration of DHEA within the past 3 months
Patient using any investigational agents within the longer of 30 days or 10 half-lives of the agent
Patient with any condition which in the Investigator's or sponsor's opinion is sufficient to prevent adequate compliance with the study or likely to confuse follow-up evaluation (e.g.. alcoholism, drug addiction, acute withdrawal from chemical dependency, psychiatric disease)
Patient requires treatment/medication prohibited by protocol
Patient with any serious EKG abnormality as determined by the Investigator
